Evaxion announces phase 2 clinical trial update: first patient completed dosing with personalized cancer vaccine evx-01

Copenhagen, denmark, april 17, 2024 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, announces that the first patient in its evx-01 phase 2 trial in metastatic melanoma received the last vaccine dose in combination with keytruda® (nct05309421).
EVAX Ratings Summary
EVAX Quant Ranking